Kidney
S2200 (JIT – IF A POSSIBLE PATIENT IS IDENTIFIED, NOTIFY CRA ASAP AS IT WILL TAKE TIME TO OPEN TRIAL THROUGH NCORP)
A Phase II Randomized Trial of Cabozantinib (NSC #761968) with or without Atezolizumab (NSC #783608) in Patients with Advanced Papillary Renal Cell Carcinoma (PAPMET2)
ALLIANCE A212102 **AT MBMC ONLY** ** As of 2/22/23 participants without a cancer diagnosis will be Temporarily Closed to Enrollment** **White female participants under (<) age 60 without a cancer diagnosis will temporarily be suspended on 12/1/22 3:30 cst**
Blinded Reference Set For Multicancer Early Detection Blood Tests
URCC 19075 **MBMC ONLY** (Temporarily Closed to Enrollment)
Multi-Center Randomized Controlled Phase II Trial of Exercise to Treat Chemotherapy-Induced Peripheral Neuropathy (CIPN)
A222004 (JIT – If a possible patient is identified, notify CRA asap as it will take time to open trial through NCORP)
A Randomized Phase III Trial of Olanzapine Versus Megestrol Acetate for Cancer-Associated Anorexia
URCC-21038
Disparities in REsults of Immune Checkpoint Inhibitor Treatment (DiRECT): A Prospective Cohort Study of Cancer Survivors Treated with anti-PD-1/anti-PD-L1 Immunotherapy in a Community Oncology Setting
S1931
Phase III Trial of Immunotherapy-Based Combination Therapy with or Without Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma (PROBE Trial)
URCC 18007
Randomized Placebo Controlled Trial of Bupropion For Cancer Related Fatigue
A031704
PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab Vs. VEGF TKI Cabozantinib with Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell CancEr [PDIGREE]
A031702 (Penile Cohort Suspended 3/13/20, Miscellaneous GU Tract Variants Cohort suspended 7/20/20, Small Cell Carcinoma/ Neuroendocrine of the Bladder Cohort suspended 4/21/21, Adenocarcinoma of the Bladder Cohort Closed 11/9/20, Renal Medullary Cohort suspended 6/23/21, Sarcomatoid Renal Cell Carcinoma suspended 8/12/21, Cohort C: Squamous Cell Carcinoma of the Bladder temporarily suspended 4/7/22 )
Phase II Study of Cabozantinib in Combination with Nivolumab and Ipilimumab in Rare Genitourinary Tumors